BRAF and MEK inhibitors increase PD-1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD-1 antibody
Open accessPublished version of a preprint
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Abstract Purpose: BRAF and MEK inhibitors (BRAF/MEKi) favor melanoma-infiltrating lymphocytes, providing the rationale for current combinatorial trials with anti–PD-1 antibody. A portion of melanoma cells may express PD-1, and anti–PD-1 antibody could have a direct antitumor effect. Here, we explore whether BRAF/MEKi modulate rates of PD-1+ melanoma cells, supporting an additional—lymphocyte-independent—basis for their therapeutic combination with anti–PD-1 antibody. Experimental Design: With data mining and flow cytometry, we assessed PD-1, PD-L1/2 expression on melanoma cell lines (CCLE, N = 61; validation cell lines, N = 7) and melanoma tumors (TCGA, N = 214). We explored in vitro how BRAF/MEKi affect rates of PD-1+, PD-L1/2+ melanoma cells, and characterized the proliferative and putative stemness features of PD-1+ melanoma cells. We tested the functional lymphocyte-independent effect of anti–PD-1 antibody alone and in combination with BRAF/MEKi in vitro and in an in vivo immunodeficient murine model. Results: PD-1 is consistently expressed on a small subset of melanoma cells, but PD-1+ cells increase to relevant rates during BRAF/MEKi treatment [7.3% (5.6–14.2) vs. 1.5% (0.7–3.2), P = 0.0156; N = 7], together with PD-L2+ melanoma cells [8.5% (0.0–63.0) vs. 1.5% (0.2–43.3), P = 0.0312; N = 7]. PD-1+ cells proliferate less than PD-1− cells (avg. 65% less; t = 7 days) and are preferentially endowed with stemness features. In vivo, the direct anti-melanoma activity of PD-1 blockage as monotherapy was negligible, but its association with BRAF/MEKi significantly delayed the development of drug resistance and tumor relapse. Conclusions: BRAF/MEKi increase the rates of PD-1+ melanoma cells that may sustain tumor relapse, providing a lymphocyte-independent rationale to explore combinatory strategies with anti–PD-1 antibody. Clin Cancer Res; 24(14); 3377–85. ©2018 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD-1 + melanoma cells emerging upon BRAF/MEK co-inhibition display limited proliferative potential and increased stemness features, potentially constituting the major source of chemoresistance (Sanlorenzo et al., 2018)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Sanlorenzo et al., 2018
Experimental — accuracy not yet measuredIn the citing paper
“the ability of BRAF and MEK co-inhibition to upregulate not only PD-L1 and PDCD1 ligand 2 (PDCD1LG2, best known as PD-L2) but also PD-1, on the surface of malignant cells (Sanlorenzo et al., 2018)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Sanlorenzo et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 1×
“These ligands bind and activate the programmed deathreceptor 1 (PD-1) on T-lymphocytes and suppress the antitumor response (5), whereas its blockage—by anti–PD-1 antibody— restores the antitumor effect.”
Follenzi, A., Ailles, L. E., Bakovic, S., Geuna, M., & Naldini, L. (2000) · Nature Genetics · doi:10.1038/76095 · Cited by 927
Mechanisms of chemoresistance in cancer stem cells
Abdullah, L. N., & Chow, E. K. (2013) · Clinical and Translational Medicine · doi:10.1186/2001-1326-2-3 · Cited by 721
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F., Hersey, P., & Scolyer, R. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2479 · Cited by 652 · cited 1×
“This increase of tumor-infiltrating lymphocytes following BRAF/MEKi treatment is well documented (3, 4), but the tumors may evade the immune system through expressionof programmeddeath-receptor-ligand 1 (PD-L1) and2 (PD-L2).”
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70024-x · Cited by 640 · cited 1×
“BRAF and MEK inhibitor combinations are currently widely used in the treatment of BRAF mutant melanoma patients (20), and MEK inhibitors showed efficacy in the treatment of NRAS mutant melanoma (21,22).”
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Kleffel, S., Posch, C., Barthel, S. R., Mueller, H., Schlapbach, C., Guenova, E., Elco, C. P., Lee, N., Juneja, V. R., Zhan, Q., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.052 · Cited by 639 · cited 8×
“Differently from previously published findings in the same mouse model (7), anti-PD1 antibody alone did not affect melanoma tumor growth in our hands.”
BackgroundMethodResultInfluentialNon-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 600 · cited 7×
“org Clin Cancer Res; 24(14) July 15, 2018 3379”
InfluentialImproved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
Hu-Lieskovan, S., Mok, S., Homet Moreno, B., Tsoi, J., Robert, L., Goedert, L., Pinheiro, E. M., Koya, R. C., Graeber, T. G., Comin-Anduix, B., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4691 · Cited by 563
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Rizos, H., Menzies, A. M., Pupo, G. M., Carlino, M. S., Fung, C., Hyman, J., Haydu, L. E., Mijatov, B., Becker, T. M., Boyd, S. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3122 · Cited by 547 · cited 2×
“Such putative cancer stem cells could contribute to the development of drug resistance and tumor relapse (8–10), which is a main issue for patients treated with BRAF/MEKi (11–13).”
Dummer, R., Schadendorf, D., Ascierto, P. A., Arance, A., Dutriaux, C., Di Giacomo, A. M., Rutkowski, P., Del Vecchio, M., Gutzmer, R., Mandala, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30180-8 · Cited by 499 · cited 1×
“BRAF and MEK inhibitor combinations are currently widely used in the treatment of BRAF mutant melanoma patients (20), and MEK inhibitors showed efficacy in the treatment of NRAS mutant melanoma (21,22).”
Cited by
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
“523,524 528 To enhance therapeutic ef fi cacy, a wide range of adaptive responses must be studied, including therapy resistance mechanisms and autophagy, which enable drug sequestration and cell survival.”
BackgroundKakadia, S., Yarlagadda, N., Awad, R., Kundranda, M., Niu, J., Naraev, B., Mina, L., Dragovich, T., Gimbel, M., & Mahmoud, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s182721 · Cited by 277
“48,69,70 Adding MEK inhibitors to BRAFi can overcome resistance to BRAFi and enhance Montagut et al 37 Paraiso et al 38”
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth
Li, Y., Elmén, L., Segota, I., Xian, Y., Tinoco, R., Feng, Y., Fujita, Y., Segura Muñoz, R. R., Schmaltz, R., Bradley, L. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.035 · Cited by 189
“Increasing attention is being paid to the effects of MEKi, which target a signaling pathway often deregulated in tumors, on immune system components (Sanlorenzo et al., 2018; Yue et al., 2018).”
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165
Metadata
- Authors
- Sanlorenzo, M., Vujic, I., Floris, A., Novelli, M., Gammaitoni, L., Giraudo, L., Macagno, M., Leuci, V., Rotolo, R., Donini, C., Basiricò, M., Quaglino, P., Fierro, M. T., Giordano, S., Sibilia, M., Carnevale-Schianca, F., Aglietta, M., & Sangiolo, D.
- Affiliations
- Comprehensive Cancer Center Vienna (AT)
- Krankenanstalt Rudolfstiftung der Stadt Wien (AT)
- University of Turin (IT)
- Candiolo Cancer Institute (IT)
- 6Division of Medical Oncology—Experimental Cell Therapy, Candiolo Cancer Institute, FPO—IRCCS, Candiolo, Turin, Italy.
- Corresponding author
- Sanlorenzo, Martina
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2018-07-15
- Volume
- 24
- Issue
- 14
- Pages
- 3377-3385
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2798102020
- Cited by
- 47
- References
- 23
- Citations by year
- 2025: 6 · 2024: 7 · 2023: 5 · 2022: 8 · 2021: 8 · 2020: 5 · 2019: 5 · 2018: 3
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Ministero della Salute (Ministry of Health, Italy) (FPRC ONLUS 5x1000, GR-2011-02349197)
- Associazione Italiana per la Ricerca sul Cancro (AIRC) (MFAG 2014 N.15731, IG20259)
- Università degli Studi di Torino (UNITO) (Fondo Ricerca Locale 2013)
- L'Oreal Italia (For Women in Science)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- BRAF/MEK inhibitors, PD-1, melanoma, anti-PD-1, PD-L1, PD-L2, tumor recurrence, drug resistance, combination therapy, melanoma cell lines, immunotherapy, tumor microenvironment, tumor cell proliferation, immunodeficient mice
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Cell Cycle, Disease Models, Animal, Drug Synergism, Humans, Lymphocytes, Melanoma, Mice, Transgenic, Gene Expression, Genes, Reporter, Mitogen-Activated Protein Kinase Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BRAF and MEK inhibitors increase PD-1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD-1 antibody. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-1914
- The paper
- Sanlorenzo, M., Vujic, I., Floris, A., Novelli, M., Gammaitoni, L., Giraudo, L., Macagno, M., Leuci, V., Rotolo, R., Donini, C., Basiricò, M., Quaglino, P., Fierro, M. T., Giordano, S., Sibilia, M., Carnevale-Schianca, F., Aglietta, M., & Sangiolo, D. (2018). BRAF and MEK inhibitors increase PD-1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD-1 antibody. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1914
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.